Expanding the muscle imaging spectrum in dysferlinopathy: description of an outlier population from the classical MRI pattern.


Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
04 2023
Historique:
received: 25 11 2022
revised: 13 02 2023
accepted: 15 02 2023
medline: 11 4 2023
pubmed: 28 3 2023
entrez: 27 3 2023
Statut: ppublish

Résumé

Dysferlinopathy is a muscle disease characterized by a variable clinical presentation and is caused by mutations in the DYSF gene. The Jain Clinical Outcome Study for Dysferlinopathy (COS) followed the largest cohort of patients (n=187) with genetically confirmed dysferlinopathy throughout a three-year natural history study, in which the patients underwent muscle function tests and muscle magnetic resonance imaging (MRI). We previously described the pattern of muscle pathology in this population and established a series of imaging criteria for diagnosis. In this paper, we describe the muscle imaging and clinical features of a subgroup of COS participants whose muscle imaging results did not completely meet the diagnostic criteria. We reviewed 184 T1-weighted (T1w) muscle MRI scans obtained at the baseline visit of the COS study, of which 106 were pelvic and lower limb only and 78 were whole-body scans. We identified 116 of the 184 patients (63%) who did not meet at least one of the established imaging criteria. The highest number found of unmet criteria was four per patient. We identified 24 patients (13%) who did not meet three or more of the nine established criteria and considered them as "outliers". The most common unmet criterion (27.3% of cases) was the adductor magnus being equally or more affected than the adductor longus. We compared the genetic, demographic, clinical and muscle function data of the outlier patients with those who met the established criteria and observed that the outlier patients had an age of disease onset that was significantly older than the whole group (29.3 vs 20.5 years, p=0.0001). This study expands the phenotypic muscle imaging spectrum of patients with dysferlinopathy and can help to guide the diagnostic process in patients with limb girdle weakness of unknown origin.

Identifiants

pubmed: 36972667
pii: S0960-8966(23)00028-7
doi: 10.1016/j.nmd.2023.02.007
pii:
doi:

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

349-357

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declarations of Competing Interest Authors have no conflict of interest related to the content of this paper.

Auteurs

Laura Llansó (L)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK; Hospital Clínic de Barcelona, Department of Neurology, Universitat de Barcelona, Spain.

Ursula Moore (U)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK.

Carla Bolano-Diaz (C)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK.

Meredith James (M)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK.

Andrew M Blamire (AM)

Magnetic Resonance Centre, Institute for Translational Medicine, Newcastle University.

Pierre G Carlier (PG)

AIM & CEA NMR Laboratory, Institute of Myology, Pitié-Salpêtrière University Hospital, Paris, France.

Laura Rufibach (L)

The Jain Foundation, Seattle, Washington, USA.

Heather Gordish-Dressman (H)

Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, DC, USA.

Georgina Boyle (G)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK.

Heather Hilsden (H)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK.

John W Day (JW)

Department of Neurology and Neurological Sciences, Stanford University School of Medicine; Stanford, CA, USA.

Kristi J Jones (KJ)

Kids Neuroscience Centre, Sydney Children's Hospitals Network. Sydney Medical School, University of Sydney.

Diana X Bharucha-Goebel (DX)

Department of Neurology Children's National Health System, Washington, DC, USA.

Emmanuelle Salort-Campana (E)

Neuromuscular and ALS center, La Timone Hospital, Aix-Marseille Université, Marseille, France.

Alan Pestronk (A)

Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

Maggie C Walter (MC)

Friedrich-Baur-Institute, Dept. of Neurology, Ludwig-Maximilians-University of Munich, Germany.

Carmen Paradas (C)

Neuromuscular Unit, Department of Neurology, Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla, Sevilla, Spain.

Tanya Stojkovic (T)

Institut de Myologie, AP-HP, G.H. Pitié-Salpêtrière, Paris, France.

Madoka Mori-Yoshimura (M)

Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry Tokyo, Japan.

Elena Bravver (E)

Carolinas Healthcare System Neurosciences Institute, Charlotte, NC, USA.

Elena Pegoraro (E)

Department of Neuroscience, University of Padova, Italy.

Jerry R Mendell (JR)

Nationwide Children's Hospital, Columbus, OH, USA.

Volker Straub (V)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK.

Jordi Díaz-Manera (J)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle Upon Tyne, UK. Electronic address: Jordi.diaz-manera@newcastle.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH